Publications and Presentations

Balstilimab: Anti-PD-1 Antibody

European Society for Medical Oncology (ESMO) Virtual

Sept 16-21, 2021

Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC). O'Malley, et al.

European Society for Medical Oncology (ESMO) Virtual

Sept 16-21, 2021

Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028). Randall, et al.

Gynecologic Oncology

August 25, 2021

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. O'Malley, et al.

American Society of Clinical Oncology (ASCO)

June 3-7, 2021

Differentiated Activity Profile for the PD-1 Inhibitor Balstilimab. C.Joyce, et al.

SGO 2021 Virtual Annual Meetings on Women's Cancer Abstracts

March 19-22, 2021

RaPiDS (GOG-3028): A Randomized Phase II Study of Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer. O'Malley, et al.

Oncogene

January 26, 2021

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Grossman, et al.

European Society for Medical Oncology (ESMO) Virtual

September 19-21, 2020

Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4) for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials . O'Malley, et al.

Society for Immunotherapy of Cancer (SITC)

November 6-10, 2019

Single-agent Activity of a Novel PD-1 Inhibitor, AGEN2034, in Recurrent Ovarian Cancer. O’Malley, et al.

European Society for Medical Oncology (ESMO)

October 19-23, 2018

Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer. Drescher, et al.

European Society for Medical Oncology (ESMO)

October 19-23, 2018

Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors. Coward et al.

American Society of Clinical Oncology (ASCO)

June 1-5, 2018

Phase One Open-Label, Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation. Moore, et al.

American Association for Cancer Research (AACR)

April 14-18, 2018

Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors. de Souza, et al.

Society for Immunotherapy of Cancer (SITC)

November 9-12, 2017

AGEN2034, a Novel anti-PD-1 Antibody that Combines Effectively With CTLA-4 Pathway Blockade to Enhance T Cell Activity. Chand, et al.

Zalifrelimab: Anti-CTLA-4 Antibody

European Society for Medical Oncology (ESMO) Virtual

Sept 16-21, 2021

Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC). O'Malley, et al.

European Society for Medical Oncology (ESMO) Virtual

Sept 16-21, 2021

Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028). Randall, et al.

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer. O'Malley, et al.

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822). Perez, et al.

European Society for Medical Oncology (ESMO) Virtual

September 19-21, 2020

Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4) for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials . O'Malley, et al.

Journal for ImmunoTherapy of Cancer

August 8, 2019

Angiosarcoma Patients Treated with Immune Checkpoint Inhibitors: A Case Series of Seven Patients from a Single Institution. Florou, et al.

PLOS

April 4, 2018

Toxicological and Pharmacological Assessment of AGEN1884, a Novel Human IgG1 anti-CTLA-4 Antibody. Gombos, et al.

European Society for Medical Oncology (ESMO)

October 19-23, 2018

Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors. Coward, et al.

American Society of Clinical Oncology (ASCO)

June 1-5, 2018

Phase One Open-Label, Ascending Dose Trial of AGEN1884, an Anti-CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection for Combination with PD-1 Blockade. Wilky, et al.

American Association for Cancer Research (AACR)

April 14-18, 2018

Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors. de Souza, et al.

Society for Immunotherapy of Cancer (SITC)

November 9-12, 2017

Characterization of the anti-CTLA-4 Antibody AGEN1884, Including Toxicology and Pharmacology Assessments in Non-human Primates. Gombos, et al.

American Society of Clinical Oncology (ASCO)

June 2-6, 2017

Phase 1, Open-Label, Multiple-Ascending-Dose Trial of AGEN1884, an Anti–CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies. Wilky, et al.

American Association for Cancer Research (AACR)

April 1-5, 2017

AGEN1884, an IgG1 anti-CTLA-4 Antibody, Combines Effectively with PD-1 Blockade in Primary Human T Cell Assays and in a Non-human Primate Pharmacodynamic (PD) Model. Drouin, et al.

American Association for Cancer Research (AACR)

April 16-20, 2016

AGEN1884 and AGEN2041: Two Functionally Distinct anti-CTLA-4 Antagonist Antibodies. Drouin, et al.

AGEN1181: Multipurpose, second-generation CTLA-4

American Association for Cancer Research (AACR)

April 9-14, 2021

Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors. Tanne, et al.

American Association for Cancer Research (AACR)

April 9-14, 2021

Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab. Shapiro, et al.

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy. O'Day, et al.

American Association for Cancer Research (AACR)

June 22-24, 2020

Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors. Tanne, et al.

American Society of Clinical Oncology (ASCO)

May 29-31, 2020

AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies. O'Day, et al.

Protein and Antibody Engineering Summit (PEGS)

November 18, 2019

New mechanistic insights from TME reconditioning by an Fc engineered anti-CTLA-4 antibody. Vincent, et al.

Cancer Cell

June 11, 2018

Selective FcgR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Waight, et al.

AGEN2373: CD137 Agonist Antibody

American Society of Clinical Oncology (ASCO)

June 3-7, 2021

Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors. Tolcher, et al.

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects. Galand, et al.

Society for Immunotherapy of Cancer (SITC)

November 7-11, 2018

AGEN2373 is a Conditionally-Active Agonist Antibody Targeting the Co-Stimulatory Receptor CD137 for the Treatment of Human Malignancies. Galand, et al.

AGEN1327: Anti-TIGIT Antibody

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity. Ward, et al.

American Association for Cancer Research (AACR)

March 29-April 3, 2019

FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses. Chand, et al.

Cancer Cell

June 11, 2018

Selective FcgR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Waight, et al.

INCAGN02385: Anti-LAG-3 Antibody

American Association for Cancer Research (AACR)

April 14-18, 2018

INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies. Savitsky, et al.

INCAGN02390: Anti-TIM-3 Antibody

American Association for Cancer Research (AACR)

April 14-18, 2018

INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3. Waight, et al.

INCAGN1876: GITR Agonist Antibody

American Association for Cancer Research (AACR)

April 1-5, 2017

INCAGN1876, a Unique GITR Agonist Antibody That Facilitates GITR Oligomerization. Gonzalez, et al.

American Association for Cancer Research (AACR)

April 16-20, 2016

A Novel Agonist Antibody (INCAGN01876) That Targets the Costimulatory Receptor GITR. Gonzalez, et al.

INCAGN1949: OX40 Agonist Antibody

American Association for Cancer Research (AACR)

April 1-5, 2017

INCAGN1949, an Anti-OX40 Antibody With an Optimal Agonistic Profile and the Ability to Selectively Deplete Intratumoral Regulatory T Cells. Gonzalez, et al.

American Association for Cancer Research (AACR)

April 16-20, 2016

INCAGN01949: A Novel Anti-OX40 Agonist Antibody With the Potential to Enhance Tumor Specific T-cell Responsiveness, While Selectively Depleting Intratumoral Regulatory T Cells. Gonzalez, et al.

VISION

Society for Immunotherapy of Cancer (SITC)

November 9-14, 2020

Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro. Pabla, et al.

AI Powered Drug Discovery and Manufacturing (AIDM)

February 27-28, 2020

Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors. Pabla, et al.

Society for Immunotherapy of Cancer (SITC)

November 6-10 2019

Driving T cell Dysfunction in Vitro for Rational Immunotherapy Design. Joyce, et al.

Cell therapy

Society for Immunotherapy of Cancer (SITC)

November 9-14 2020

AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing. Burcu, et al.

Society for Immunotherapy of Cancer (SITC)

November 6-10 2019

TCR Fingerprinting and Off-Target Peptide Identification. Karapetyan, et al.

Frontiers in Immunology

October 22, 2019

TCR Fingerprinting and Off-Target Peptide Identification. Karapetyan, et al.

QS-21 Stimulon® Adjuvant

New England Journal of Medicine

September 15, 2016

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. Cunningham, et al.

New England Journal of Medicine

November 17, 2011

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. RTS,S Clinical Trials Partnership, et al.

Expert Review of Vaccines

April 2011

Recent Clinical Experience With Vaccines Using MPL- And QS-21-Containing Adjuvant Systems. Garçon, et al.

Vaccine

August 11, 2011

Four Year Immunogenicity of the RTS,S/AS02(A) Malaria Vaccine in Mozambican Children During a Phase IIb Trial. Aide, et al.

The Journal of Infectious Diseases

July 1, 2011

Effect of the Pre-Erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. Bejon, et al.

The Lancet Infectious Diseases

October 1, 2011

Safety and Efficacy of the RTS,S/AS01E Candidate Malaria Vaccine Given With Expanded-Programme-On-Immunisation Vaccines: 19 Month Follow-Up of a Randomised, Open-Label, Phase 2 Trial. Asante, et al.

Vaccine

November 3, 2011

Safety and Immunogenicity of Long HSV-2 Peptides Complexed with rhHsc70 in HSV-2 Seropositive Persons. Wald, et al.

Vaccine

November 3, 2011

A Heat Shock Protein Based Polyvalent Vaccine Targeting HSV-2: CD4(+) and CD8(+) Cellular Immunity and Protective Efficacy. Mo, et al.

Kidney International

February 1, 2010

Rapid, Enhanced, and Persistent Protection of Patients with Renal Insufficiency by AS02(V)-Adjuvanted Hepatitis B Vaccine. Surquin, et al.

New England Journal of Medicine

December 11, 2008

Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants. Abdulla, et al.

New England Journal of Medicine

December 11, 2008

Efficacy of RTS,S/AS01E Vaccine Against Malaria in Children 5 to 17 Months of Age. Bejon, et al.

Expert Opinion on Biological Therapy

June 12, 2008

Cancer Immunotherapy Targeting Tumour-Specific Antigens: Towards a New Therapy for Minimal Residual Disease. Brichard, et al.

Vaccine

March 4, 2008

Vaccine Adjuvant Systems Containing Monophosphoryl Lipid A and QS21 Induce Strong and Persistent Humoral and T Cell Responses Against Hepatitis B Surface Antigen in Healthy Adult Volunteers. Vandepapelière, et al.

The Journal of Immunology

July 15, 2005

Induction of Humoral and CD8+ T Cell Responses are Required for Protection Against Lethal Ebola Virus Infection. Warfiled, et. al.

Clinical Cancer Research

May 2002

T-cell Responses Against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund's Adjuvant, Granulocyte Macrophage Colony-Stimulating Factor, and QS-21 as Immunological Adjuvants. Schaed, et al.

The Journal of Immunology

February 15, 2001

Oral QS-21 Requires Early IL-4 Help for Induction of Mucosal and Systemic Immunity. Boyaka, et al.

Vaccine

February 28, 2001

QS-21 Promotes an Adjuvant Effect Allowing for Reduced Antigen Dose During HIV-1 Envelope Subunit Immunization in Human. Evans, et al.

Vaccine

July 16, 2001

Three Double-Blind, Randomized Trials Evaluating the Safety and Tolerance of Different Formulations of the Saponin Adjuvant QS-21. Waite, et al.

The Journal of Infectious Diseases

November 1, 2009

Synthetic Malaria Peptide Vaccine Elicits High Levels of Antibodies in Vaccinees of Defined HLA Genotypes. Nardin, et al.

Vaccine

November 12, 1999

Comparison of the Effect of Different Immunological Adjuvants on the Antibody and T Cell Response to Immunization with MUC1-KLH and GD3-KLH Conjugate Cancer Vaccines. Kim, et al.

Journal of Virology

June 1998

Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated With QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes. Sasaki, et al.

New England Journal of Medicine

January 9, 1997

A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria. RTS,S Malaria Vaccine Evaluation Group. Stoute, et al.

Carbohydrate Research

January 4, 1996

Structure of the saponin adjuvant QS-21 and its Base-Catalyzed Isomerization Product by 1H and Natural Abundance 13C NMR Spectroscopy. Jacobsen, et al.

Cancer Research

July 1, 1995

GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21. Helling, et al.

Critical Reviews in Therapeutic Drug Carrier Systems

1996

Saponins as Vaccine Adjuvants. Kensil, CR.

The Journal of Immunology

April 15, 1992

Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses. Newman, et al.

The Journal of Immunology

January 15, 1991

Separation and Characterization of Saponins With Adjuvant Activity From Quillaja Saponaria Molina Cortex. Kensil, et al.

AutoSynVaxTM: Individualized cancer neoantigen vaccine

Society for Immunotherapy of Cancer (SITC)

Novemeber 1, 2018

A Phase 1 Study of Safety and Tolerability of AGEN2003 Vaccine in Patients With Advanced Cancer. Wesolowski, et al.

American Association for Cancer Research (AACR)

April 1-5, 2017

Agenus' Next Generation Cancer Vaccine Platforms. Uduman, et al.

PhosphoSynVaxTM: Off-the-shelf cancer neoantigen vaccine

Nature

December 6, 2019

Murine Xenograft Bioreactors for Human Immunopeptidome Discovery. Heather, et al.

Touchoncology

October 17, 2019

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy – The PSV™ Platform. Myers

Society for Immunotherapy of Cancer (SITC)

November 7-11, 2018

Identification of Shared Phosphopeptide Tumor Targets in Colorectal Cancer for Novel Off-the-shelf Vaccine Development. Myers, et al.

Next Gen Immuno-Oncology Congress Presentation

June 21, 2018

The Remarkable Efficiency of Chaperone-based Synthetic Cancer Vaccines. Levey, PhD

American Association for Cancer Research (AACR)

April 1-5, 2017

Agenus' Next Generation Cancer Vaccine Platforms. Uduman, et al.

ProphageTM: Individualized Cancer Vaccine

Clinical Cancer Research

February 13, 2017

Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Bloch, et al.

Neuro-Oncology

December 12, 2013

Heat-shock Protein Peptide complex-96 Vaccination for Recurrent Glioblastoma: A Phase II, Single-Arm Trial. Bloch, et al.

Clinical Cancer Research

August 7, 2012

Individual Patient-Specific Immunity Against High-Grade Glioma After Vaccination With Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein. Crane, et al.

Journal of Translational Medicine

January 29, 2010

Autologous Tumor-Derived Heat-shock Protein Peptide Complex-96 (HSPPC-96) in Patients with Metastatic Melanoma. Eton, et al.

Journal of Clinical Oncology

May 20, 2009

Survival Update from a Multicenter, Randomized, Phase III Trial of Vitespen Versus Observation as Adjuvant Therapy for Renal Cell Carcinoma in Patients at High Risk of Recurrence [meeting abstract]. Wood, et al.

Expert Opinion on Biological Therapy

February 2009

Treating Human Cancers With Heat Shock Protein-Peptide Complexes: The Road Ahead. Srivastava, et al.

The Lancet

July 3, 2008

An Adjuvant Autologous Therapeutic Vaccine (HSPPC-96; Vitespen) Versus Observation Alone for Patients at High Risk of Recurrence After Nephrectomy for Renal Cell Carcinoma: A Multicentre, Open-Label, Randomised Phase III Trial. Wood, et al.

Journal of Clinical Oncology

May 20, 2008

Phase II Feasibility Study of Autologous Vaccine (HSPPC-96) in Patients with Resectable Lung Cancer [meeting abstract]. Santis, et al.

British Journal of Cancer

April 22, 2008

Vaccination of Metastatic Renal Cell Carcinoma Patients with Autologous Tumour-Derived Vitespen Vaccine: Clinical Findings. Jonasch, et al.

Journal of Clinical Oncology

February 20, 2008

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, with Physician's Choice of Treatment for Stage IV Melanoma: the C-100-21 Study Group. Testori, et al.

Digestive Diseases and Sciences

April 10, 2007

A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma . Maki, et al.

Cancer

January 1, 2007

Experience With Heat Shock Protein-Peptide Complex 96 Vaccine Therapy in Patients With Indolent Non-Hodgkin Lymphoma . Oki, et al.

Clinical Cancer Research

June 15, 2005

Combination of Imatinib Mesylate With Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia. Li, et al.

Cancer Research

May 1 2005

Natural Killer and NK-Like T Cell Activation in Colorectal Carcinoma Patients Treated With Autologous Tumor-Derived Heat Shock Protein 96 . Pilla, et al.

The Journal of Immunology

October 1, 2003

Human Tumor-Derived Heat Shock Protein 96 Mediates in Vitro Activation and in Vivo Expansion of Melanoma And Colon Carcinoma-Specific T Cells . Rivoltini, et al.

Clinical Cancer Research

August 15, 2003

Vaccination With Autologous Tumor-Derived Heat-Shock Protein gp96 After Liver Resection for Metastatic Colorectal Cancer . Mazzaferro, et al.

Journal of Clinical Oncology

October 15, 2002

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. Belli, et al.

Cancer Research

January 1, 2001

Human Heat Shock Protein 70 Peptide Complexes Specifically Activate Antimelanoma T Cells. Castelli, et al.

International Journal of Cancer

September 13, 2000

Immunization of Cancer Patients With Autologous Cancer-Derived Heat Shock Protein gp96 Preparations: A Pilot Study. Janetzki, et al.

Other Publications

Frontiers in Immunology

August 7, 2019

Mutation-Derived Neoantigens for Cancer Immunotherapy. Castle, et al.